- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
No Successor to OCM Would Disappoint
Experts from US Oncology, Tennessee Oncology, AON, and COA dig into the details of implementing the Enhancing Oncology Model, set to take effect July 1, 2023.
EP: 1.No Successor to OCM Would Disappoint
EP: 2.CMMI Open to Feedback, but EOM Out of the Blue
EP: 3.Some Practices That Did Not Do OCM Are Applying
EP: 4.Seven Tumor Types: Pros and Cons
EP: 5.A Model That Is Built to “Win”
EP: 6.Addressing Health Equity and Social Needs
EP: 7.Is Five Years Long Enough?
EP: 8.Changes to MEOS and Barriers to Entry
EP: 9.Small Practices and Dual Risk: Considerations and Approaches
EP: 10.Does Pooling Make Sense?
EP: 11.What Would You Change About the EOM?
Moderator Stuart Staggs, MSIE, senior director, strategic programs, The US Oncology Network, starts the discussion of the Enhancing Oncology Model by asking panelists to reflect on the need for CMS to provide a successor to the Oncology Care Model (OCM). Stephen Schleicher, MD, MBA, chief medical officer, Tennessee Oncology; Kashyap Patel, MD, CEO, Carolina Blood and Cancer Care Associates and president, Community Oncology Alliance; and Fred Divers, MD, chief medical officer, American Oncology Network and medical oncologist, Genesis Cancer and Blood Institute of Arkansas, agree that practices that had invested in practice transformation under the OCM would have been extremely disappointed if there had been no successor to the OCM.
Clinical Characteristics, Outcomes of Patients With Plaque Psoriasis on Tapinarof Cream
December 5th 2023Two posters presented at the 2023 Fall Clinical Dermatology Conference examined patient demographics, clinical characteristics, and outcomes in patients with plaque psoriasis treated with tapinerof cream.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Imetelstat Offers Benefits for Patients With MDS Who Are Red Blood Cell–Transfusion Dependent
December 5th 2023The past year has offered new hope for patients with lower-risk myelodysplastic syndromes. Besides imetelstat, which has an FDA deadline for action of June 2024, the agency approved luspatercept, which has a different mechanism of action.
Read More
